© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
A panel of oncologists, patients, and a patient advocate discuss the emergence of comprehensive molecular testing in lung and thyroid cancer and consider how results can be used to inform treatment, as was done in 2 real-world cases highlighted.
June 2nd 2021
Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, describes how molecular testing in non–small cell lung cancer has advanced and impacted treatment.
Lori J. Wirth, MD, of Massachusetts General Hospital, comments on the role of molecular testing to guide treatment decisions in thyroid cancer and explains how personalized medicine differs from standard treatment approaches.
June 9th 2021
Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.
Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.
CNN Anchor Christiane Amanpour Receiving Treatment for Ovarian Cancer
Standing Firm Against the Financial Burden of Cancer
Yescarta Associated With Better Outcomes Than Other Available Treatments for Relapsed/Refractory Follicular Lymphoma
When Cancer Hits Close to Home